In yesterday’s Wall Street session, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) shares traded at $4.42, down -3.49% from the previous session.
6 analysts cover EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $52.00 and a low of $21.00, we find $30.50. Given the previous closing price of $4.58, this indicates a potential upside of 565.94 percent. EYPT stock price is now -32.76% away from the 50-day moving average and -52.75% away from the 200-day moving average. The market capitalization of the company currently stands at $151.61M.
The stock has received a hold rating from 0 analysts and a buy rating from 6. Brokers who have rated the stock have averaged $32.33 as their price target over the next twelve months.
With the price target of $21, Chardan Capital Markets recently initiated with Buy rating for EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT). On March 01, 2021, Cowen recently initiated its ‘Outperform’ rating on the stock quoting a target price of $25, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’.
In other news, Pine Michael Craig, Chief Corp Dev.&Strat. Officer bought 1,000 shares of the company’s stock on Mar 14. The stock was bought for $12,210 at an average price of $12.21. Upon completion of the transaction, the Chief Corp Dev.&Strat. Officer now directly owns 1,000 shares in the company, valued at $4420.0. Insiders disposed of 5,618 shares of company stock worth roughly $24831.56 over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EYPT stock. A new stake in EyePoint Pharmaceuticals Inc. shares was purchased by MONASHEE INVESTMENT MANAGEMENT LLC during the first quarter worth $972,000. GSA CAPITAL PARTNERS LLP invested $97,000 in shares of EYPT during the first quarter. In the first quarter, JANE STREET GROUP, LLC acquired a new stake in EyePoint Pharmaceuticals Inc. valued at approximately $92,000. DYNAMIC TECHNOLOGY LAB PRIVATE LTD acquired a new stake in EYPT for approximately $57,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP purchased a new stake in EYPT valued at around $56,000 in the second quarter.
During the past 12 months, EyePoint Pharmaceuticals Inc. has had a low of $4.53 and a high of $21.50. As of last week, the company has a debt-to-equity ratio of 0.29, a current ratio of 5.60, and a quick ratio of 5.50.
The company reported revenue of $10.01 million for the quarter, compared to $9.06 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10.52 percent.